Franklin Genomic Advancements ETF (BATS:HELX) Short Interest Update

Franklin Genomic Advancements ETF (BATS:HELX) saw a significant increase in short interest in June. As of June 30th, there was short interest totaling 15,981 shares, an increase of 108.6% from the June 15th total of 7,660 shares. Approximately 4.0% of the shares of the stock are short sold. Based on an average trading volume of 4,418 shares, the short-interest ratio is currently 3.6 days.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Kestra Advisory Services LLC purchased a new stake in shares of Franklin Genomic Advancements ETF in the fourth quarter worth $39,000. LPL Financial LLC grew its position in Franklin Genomic Advancements ETF by 22.4% during the fourth quarter. LPL Financial LLC now owns 11,133 shares of the company’s stock worth $404,000 after buying an additional 2,037 shares in the last quarter. Osaic Holdings Inc. grew its position in Franklin Genomic Advancements ETF by 19.1% during the second quarter. Osaic Holdings Inc. now owns 3,132 shares of the company’s stock worth $87,000 after buying an additional 502 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Franklin Genomic Advancements ETF in the 2nd quarter worth about $42,000.

Franklin Genomic Advancements ETF Price Performance

BATS HELX opened at $39.49 on Wednesday. Franklin Genomic Advancements ETF has a 1 year low of $26.99 and a 1 year high of $41.30. The stock has a market capitalization of $15.80 million, a PE ratio of 26.71 and a beta of 1.05. The company’s 50 day simple moving average is $36.34 and its two-hundred day simple moving average is $35.29.

About Franklin Genomic Advancements ETF

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton.